Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis

Bibliographic Details
Main Authors:	Luqmani, R, Mukhtyar, C, Flossmann, O, Hellmich, B, Jayne, D
Format:	Journal article
Published:	2007

Similar Items

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force
by: Mukhtyar, C, et al.
Published: (2007)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

The role of biologic therapies in the management of systemic vasculitis.
by: Chan, A, et al.
Published: (2006)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis
by: Hellmich, B, et al.
Published: (2006)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Outpatient assessment of systemic vasculitis.
by: Nataraja, A, et al.
Published: (2007)

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Outcome in small-vessel systemic vasculitis.
by: Luqmani, R, et al.
Published: (2006)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
by: Flossmann, O, et al.
Published: (2006)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
by: Luqmani, R
Published: (2013)

The future of damage assessment in vasculitis.
by: Seo, P, et al.
Published: (2007)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
by: Luqmani, R, et al.
Published: (1999)

Eular recommendations for vasculitis
by: Luqmani, R, et al.
Published: (2007)

Cardiovascular involvement in primary systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2009)

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
by: Mukhtyar, C, et al.
Published: (2008)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis.
by: de Groot, K, et al.
Published: (2003)

Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.
by: Mukhtyar, C, et al.
Published: (2007)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
by: Mukhtyar, C, et al.
Published: (2008)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
by: Luqmani, R, et al.
Published: (2009)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
by: Mukhtyar, C, et al.
Published: (2007)

Clinical and biological assessment in systemic necrotizing vasculitides.
by: Mukhtyar, C, et al.
Published: (2006)

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
by: Flossmann, O, et al.
Published: (2009)

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
by: Suppiah, R, et al.
Published: (2011)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2007)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2008)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Hellmich, B, et al.
Published: (2007)

USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS
by: Mukhtyar, C, et al.
Published: (2009)

Relapses in patients with a systemic vasculitis.
by: Gordon, M, et al.
Published: (1993)

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).
by: Mukhtyar, C, et al.
Published: (2009)

Measurement of damage in systemic vasculitis: A comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
by: Suppiah, R, et al.
Published: (2010)

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
by: Harper, L, et al.
Published: (2012)

Mortality in systemic vasculitis: a systematic review.
by: Phillip, R, et al.
Published: (2008)

Efficacy and safety of belimumab and azathioprine for maintenance of remission in ANCA-associated vasculitis: a randomized controlled study
by: Jayne, D, et al.
Published: (2019)

Validation of a new version of the Birmingbam vasculitis activity score
by: Mukhtyar, C, et al.
Published: (2008)